Date：26 July (Wednesday)
Time：09:00 – 10:40 (GMT+8)
SVP and Head of APAC, Deployment Solutions
More than 13 years of strategy and management consulting experience in Asia Pacific, most recently as a Principal in L.E.K. Consulting’s Tokyo life science and medtech practice
As a senior leader in APAC, with deep market knowledge in East Asia and Oceania, Sam has provided strategic advice to pharmaceutical, medtech and healthcare clients, with a particular focus on commercial model design and go-to-market strategies
Relevant projects have focused on: market entry, digital and traditional customer engagement, channel strategy, sales territory planning and design, and commercial excellence
Prior to that, Sam advised clients based out of Sydney, Australia. He also spent time working in L.E.K’s dedicated life science practice in the US
He holds a Bachelor of Laws (Honours) and a Bachelor of Commerce specializing in Finance from the University of Auckland, New Zealand
Each year, Syneos Health takes stock of industry developments and harvests insights that can help shape a future of sustainable outcomes. If 2022 was a year of reset, then we look to 2023 as a year of renewal and reimagining, where the senses are sharpened around what we need to learn. This year, we are asking: How do we start imagining a future and building the purposeful, personal impact that we want to have on it? What can we do to create optimism and a sense of future agency to make these positive outcomes possible? This session includes:
Digital Transformation: Start, Stall, RestartThe last few years accelerated digital transformation across life sciences, driven by shifts in both efforts and effects: efforts to protect people from COVID, and the effects those changes had on longer-term expectations for speed, ease and choice.
Bold Trajectory for Medical Affairs InnovationIn an environment of increasing complexity, re-energized feedback loops and new technology capabilities, there is an urgent need to bridge the gaps between data medical information exchange and strategy.
Outsourcing Focus in M&A Strategies
Startups and first molecule companies turn to outsourcing for the cycles of experience. As they set strategic objectives and detailed logistics plans they want to know what worked, what didn’t and how to build on the experience of similar innovators. Many startups in Asia turn to Japan as next destination to advance their development and commercialization. cells, all T cells, and bone marrow stem cells, with LNPs allowing specific delivery of gene editing and insertion systems to treat diseases such as sickle cell anemia, Nucleoside-modified mRNA will have an enormous potential in the development of new medical therapies.